TN2013000388A1 - Anticoagulant antidotes - Google Patents

Anticoagulant antidotes

Info

Publication number: TN2013000388A1
Authority: TN; Tunisia
Prior art keywords: antidotes; anticoagulant; anticoagulant antidotes; anticoagulants; relates
Prior art date: 2011-03-30

Application number

TNP2013000388A

Other languages

English (en)

Inventor

Ryn Joanne Van

Keith Canada

Robert Copenhaver

Norbert Hauel

Tobias Litzenburger

Christopher Ronald Sarko

Sanjaya Singh

Alisa K Waterman

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-30

Filing date

2013-09-26

Publication date

2015-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45876804&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000388(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-09-26 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-01-20 Publication of TN2013000388A1 publication Critical patent/TN2013000388A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Microbiology (AREA)
Mycology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Hematology (AREA)
Diabetes (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

TNP2013000388A 2011-03-30 2013-09-26 Anticoagulant antidotes TN2013000388A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161469207P	2011-03-30	2011-03-30
PCT/EP2012/055397 WO2012130834A1 (fr)	2011-03-30	2012-03-27	Antidotes aux anticoagulants

Publications (1)

Publication Number	Publication Date
TN2013000388A1 true TN2013000388A1 (en)	2015-01-20

Family

ID=45876804

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000388A TN2013000388A1 (en)	2011-03-30	2013-09-26	Anticoagulant antidotes

Country Status (23)

Country	Link
US (2)	US8821871B2 (fr)
EP (1)	EP2691156A1 (fr)
JP (1)	JP2014515740A (fr)
KR (1)	KR20140009437A (fr)
CN (1)	CN103476459A (fr)
AP (1)	AP2013007046A0 (fr)
AR (1)	AR085758A1 (fr)
BR (1)	BR112013025031A2 (fr)
CA (1)	CA2827787A1 (fr)
CL (1)	CL2013002551A1 (fr)
CO (1)	CO6771448A2 (fr)
EA (1)	EA201301090A1 (fr)
EC (1)	ECSP13012997A (fr)
IL (1)	IL227653A0 (fr)
MA (1)	MA34978B1 (fr)
MX (1)	MX2013011092A (fr)
PE (1)	PE20140964A1 (fr)
PH (1)	PH12013501924A1 (fr)
SG (1)	SG193552A1 (fr)
TN (1)	TN2013000388A1 (fr)
TW (1)	TW201302796A (fr)
UY (1)	UY33994A (fr)
WO (1)	WO2012130834A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3604339B1 (fr)	2011-01-14	2021-03-10	The Regents Of The University Of California	Anticorps thérapeutiques contre la protéine ror-1 et leurs procédés d'utilisation
CA2856540C (fr)	2011-11-29	2018-04-03	Solomon S. Steiner	Agents inversant l'effet des anticoagulants
WO2014197849A2 (fr)	2013-06-06	2014-12-11	Igenica Biotherapeutics, Inc.	Anticorps anti-c10orf54 et leurs utilisations
DK3404031T3 (da) *	2013-07-30	2020-12-14	Janssen Sciences Ireland Unlimited Co	Thieno[3,2-d]pyrimidinderivater til behandling af virusinfektioner
KR101523503B1 (ko) *	2013-09-17	2015-05-29	강원대학교산학협력단	아디포넥틴으로부터 유래한 펩타이드 및 이를 포함하는 조성물
WO2015059159A1 (fr) *	2013-10-25	2015-04-30	Boehringer Ingelheim International Gmbh	Antidotes à des anticoagulants
EP2980218A1 (fr) *	2014-07-30	2016-02-03	Rheinische Friedrich-Wilhelms-Universität Bonn	Complexe de thrombine aptamère à utiliser comme antidote à action directe sur les inhibiteurs de la thrombine
WO2019210270A2 (fr) *	2018-04-27	2019-10-31	Seattle Children's Hospital D/B/A Seattle Children's Research Institute	Thérapie génique in vivo faisant appel à l'administration d'une construction de gène lentiviral

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6087380A (en)	1949-11-24	2000-07-11	Boehringer Ingelheim Pharma Kg	Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
ATE87659T1 (de)	1986-09-02	1993-04-15	Enzon Lab Inc	Bindungsmolekuele mit einzelpolypeptidkette.
AU634186B2 (en)	1988-11-11	1993-02-18	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
HU215180B (hu)	1992-01-23	1998-10-28	Merck Patent Gmbh.	Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
DE4203965A1 (de)	1992-02-11	1993-08-12	Max Planck Gesellschaft	Antidot fuer hirudin und synthetische thrombininhibitoren
ES2325541T3 (es)	1992-08-21	2009-09-08	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
CA2150262C (fr)	1992-12-04	2008-07-08	Kaspar-Philipp Holliger	Proteines fixatrices multivalentes et multispecifiques, fabrication et utilisation
ATE183513T1 (de)	1993-06-03	1999-09-15	Therapeutic Antibodies Inc	Herstellung von antikörperfragmenten
AT404357B (de)	1995-06-13	1998-11-25	Immuno Ag	Prothrombin-derivate
DE19605126A1 (de)	1996-02-12	1997-08-14	Basf Ag	Thrombinmuteine als Antidot für Thrombininhibitoren
US6200955B1 (en)	1996-06-11	2001-03-13	Commonwealth Biotechnologies, Inc.	Heparin binding peptides
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
PE121699A1 (es)	1997-02-18	1999-12-08	Boehringer Ingelheim Pharma	Heterociclos biciclicos disustituidos como inhibidores de la trombina
AU7266898A (en)	1997-04-30	1998-11-24	Enzon, Inc.	Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US6440417B1 (en)	1998-11-06	2002-08-27	Conjuchem, Inc.	Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
US6624141B1 (en)	1999-03-17	2003-09-23	The Regents Of The University Of Michigan	Protamine fragment compositions and methods of use
JP2003530839A (ja)	2000-04-12	2003-10-21	プリンシピアファーマスーティカルコーポレイション	アルブミン融合タンパク質
AU2002241922B2 (en)	2001-01-17	2007-10-25	Aptevo Research And Development Llc	Binding domain-immunoglobulin fusion proteins
US20040097547A1 (en)	2001-04-16	2004-05-20	Taveras Arthur G.	3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
US20050214857A1 (en)	2001-12-11	2005-09-29	Algonomics N.V.	Method for displaying loops from immunoglobulin domains in different contexts
EP1517921B1 (fr)	2002-06-28	2006-06-07	Domantis Limited	Ligands a specificite double et avec une demi-vie augmentee
NZ540194A (en)	2002-11-08	2008-07-31	Ablynx Nv	Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
PL1639011T3 (pl)	2003-06-30	2009-05-29	Domantis Ltd	Pegilowane przeciwciała jednodomenowe (dAb)
BR122022001846B1 (pt)	2007-09-28	2022-12-27	Portola Pharmaceuticals, Inc.	Uso de polipeptídeo de duas cadeias para preparo de medicamento para reduzir sangramento
CN102481317B (zh)	2009-08-24	2014-09-03	贝林格尔.英格海姆国际有限公司	活性炭对达比加群酯过量给药的紧急干预
AR079944A1 (es) *	2010-01-20	2012-02-29	Boehringer Ingelheim Int	Anticuerpo neutralizante de la actividad de un anticoagulante

2012
- 2012-03-27 CA CA2827787A patent/CA2827787A1/fr not_active Abandoned
- 2012-03-27 CN CN2012800157134A patent/CN103476459A/zh active Pending
- 2012-03-27 MX MX2013011092A patent/MX2013011092A/es not_active Application Discontinuation
- 2012-03-27 PH PH1/2013/501924A patent/PH12013501924A1/en unknown
- 2012-03-27 WO PCT/EP2012/055397 patent/WO2012130834A1/fr not_active Ceased
- 2012-03-27 MA MA36273A patent/MA34978B1/fr unknown
- 2012-03-27 PE PE2013002078A patent/PE20140964A1/es not_active Application Discontinuation
- 2012-03-27 EA EA201301090A patent/EA201301090A1/ru unknown
- 2012-03-27 JP JP2014501575A patent/JP2014515740A/ja not_active Ceased
- 2012-03-27 EP EP12710300.0A patent/EP2691156A1/fr not_active Withdrawn
- 2012-03-27 AP AP2013007046A patent/AP2013007046A0/xx unknown
- 2012-03-27 SG SG2013070719A patent/SG193552A1/en unknown
- 2012-03-27 BR BR112013025031A patent/BR112013025031A2/pt not_active IP Right Cessation
- 2012-03-27 KR KR1020137025877A patent/KR20140009437A/ko not_active Withdrawn
- 2012-03-28 US US13/432,296 patent/US8821871B2/en active Active
- 2012-03-29 UY UY0001033994A patent/UY33994A/es unknown
- 2012-03-29 AR ARP120101085A patent/AR085758A1/es unknown
- 2012-03-29 TW TW101111195A patent/TW201302796A/zh unknown
2013
- 2013-07-25 IL IL227653A patent/IL227653A0/en unknown
- 2013-09-05 CL CL2013002551A patent/CL2013002551A1/es unknown
- 2013-09-20 CO CO13224736A patent/CO6771448A2/es unknown
- 2013-09-26 TN TNP2013000388A patent/TN2013000388A1/fr unknown
- 2013-10-25 EC ECSP13012997 patent/ECSP13012997A/es unknown
2014
- 2014-07-22 US US14/337,357 patent/US20140377265A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US8821871B2 (en)	2014-09-02
NZ613543A (en)	2015-07-31
WO2012130834A1 (fr)	2012-10-04
CO6771448A2 (es)	2013-10-15
KR20140009437A (ko)	2014-01-22
TW201302796A (zh)	2013-01-16
IL227653A0 (en)	2013-09-30
PE20140964A1 (es)	2014-08-17
MA34978B1 (fr)	2014-03-01
US20140377265A1 (en)	2014-12-25
CA2827787A1 (fr)	2012-10-04
AP2013007046A0 (en)	2013-08-31
UY33994A (es)	2012-09-28
MX2013011092A (es)	2013-12-06
CL2013002551A1 (es)	2014-02-14
CN103476459A (zh)	2013-12-25
EP2691156A1 (fr)	2014-02-05
AR085758A1 (es)	2013-10-23
BR112013025031A2 (pt)	2017-08-01
US20120276123A1 (en)	2012-11-01
ECSP13012997A (es)	2013-12-31
JP2014515740A (ja)	2014-07-03
EA201301090A1 (ru)	2014-05-30
SG193552A1 (en)	2013-11-29
PH12013501924A1 (en)	2017-10-25

Publication	Publication Date	Title
TN2012000366A1 (en)	2014-01-30	Anticoagulant antidotes
MX2014012978A (es)	2015-02-05	Regiones de anticuerpo modificado y sus usos.
TN2013000388A1 (en)	2015-01-20	Anticoagulant antidotes
EP2706991A4 (fr)	2015-05-06	Composition immunogène présentant de multiples antigènes, procédés et utilisations associés
PH12014501427B1 (en)	2014-09-22	Anti-phf-tau antibodies and their uses
CR20150046A (es)	2015-03-11	Anticuerpos anti-cd79b e inmunoconjugados
BR112014030278A2 (pt)	2017-06-27	anticorpo, e, composição.
EA201590993A1 (ru)	2015-11-30	Гетеродимерные иммуноглобулины
TN2015000050A1 (en)	2016-06-29	Methods of treating a tauopathy
WO2013021279A3 (fr)	2013-05-02	Anticorps fortement galactosylés
MX2013008390A (es)	2013-08-12	Preparacion de estructuras de metal-triazolato.
MX2014002053A (es)	2014-04-25	Anticuerpos anti -mcsp y metodos de uso.
PH12015501059A1 (en)	2015-07-27	Anti-hemagglutinin antibodies and methods of use
WO2012109238A3 (fr)	2012-11-01	Procédés d'augmentation des réponses immunitaires à l'aide d'agents qui se lient directement à ire-1 et activent ire-1
MX2016004802A (es)	2016-07-18	Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
WO2014097318A3 (fr)	2015-03-19	Agents pour éliminer des cellules d'initiation tumorale
EA201491455A1 (ru)	2015-01-30	ЭФФЕКТОРЫ β-АРРЕСТИНА, КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
UY35795A (es)	2015-04-30	Anticuerpos que neutralizan la actividad de dabigatran,etexilato de dabigatran y o-acilglucurónidos de dabigatran
HK1199842A1 (en)	2015-07-24	Anti-siglec-15 antibodies and uses thereof
UA70698U (ru)	2012-06-25	Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства
TH1301006508B (th)	2016-05-19	องค์ประกอบที่รวมถึงโพลีเตตระฟลูออโรเอธิลีน และกระบวนการสำหรับการเตรียมองค์ประกอบของสิ่งนั้น
CL2012001927A1 (es)	2012-12-14	Anticuerpo capaz de neutralizar la actividad de un anticoagulante de dabigatran; método de fabricación de anticuerpo; kit que comprende al anticuerpo.